The Impact of Cannabidiol on Psychiatric and Medical Conditions
Open Access
- 1 January 2020
- journal article
- review article
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 12 (7) , 393-403
Abstract
The Impact of Cannabidiol on Psychiatric and Medical ConditionsKeywords
This publication has 75 references indexed in Scilit:
- The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysisJournal of the American Pharmacists Association, 2020
- Cannabidiol (CBD) use in psychiatric disorders: A systematic reviewNeuroToxicology, 2019
- Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disordersEpilepsia, 2014
- Cannabidiol in Humans—The Quest for Therapeutic TargetsPharmaceuticals, 2012
- Safety and Side Effects of Cannabidiol, a Cannabis sativa ConstituentCurrent Drug Safety, 2011
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- Agonistic Properties of Cannabidiol at 5-HT1a ReceptorsNeurochemical Research, 2005
- (−)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferensEuropean Journal of Pharmacology, 2002
- Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man.Pharmacological Reviews, 1986
- Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic PatientsPharmacology, 1980